[2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine, a new psychotropic compound].
D000374:Aggression / Q000187:drug effects; D000438:Alcohols / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects*; D002626:Chemistry, Pharmaceutical; D006224:Cricetinae; D003864:Depression, Chemical; D004357:Drug Synergism; D005239:Fear / Q000187:drug effects; D006591:Hexobarbital / Q000494:pharmacology; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009538:Nicotine / Q000037:antagonists & inhibitors; D010078:Oxazines / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000633:toxicity; D011600:Psychopharmacology; D051381:Rats; D012640:Seizures / Q000517:prevention & control; D013057:Spectrum Analysis; D013268:Stimulation, Chemical; D014149:Tranquilizing Agents / Q000494:pharmacology*
D000438:Alcohols; D010078:Oxazines; D014149:Tranquilizing Agents; D009538:Nicotine; D006591:Hexobarbital
2-Athylamino-6-chlor-4-methyl-4-phenyl-4H-3,1-benzoxazin, eine neue, psychotrope Verbindung.